Skip to main content
  • BIOMAG-I Two-Year Study Results Confirm Excellent Safety and Efficacy Profile for Freesolve, BIOTRONIK’s Newest Resorbable Magnesium Scaffold Innovation

    New Clinical Outcomes Show Continuous Favorable Low Target Lesion Failure and Target Lesion Revascularization

    New two-year follow-up data from the BIOMAG-I first-in-human trial confirms a reliable and predictable long-term safety profile for Freesolve™, the third-generation resorbable magnesium scaffold (RMS), establishing it as a true alternative to contemporary drug-eluting stents (DES). The results were presented by Prof. Dr. Michael Haude at the EuroPCR 2024 conference yesterday in Paris. 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details